Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 10
1999 2
2000 4
2001 8
2002 9
2003 12
2004 7
2005 13
2006 4
2007 3
2008 1
2009 6
2010 15
2011 6
2012 8
2013 14
2014 11
2015 24
2016 15
2017 16
2018 22
2019 28
2020 42
2021 36
2022 36
2023 30
2024 19
2025 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

356 results

Results by year

Filters applied: . Clear all
Page 1
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).
Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, Honda G, Matsumoto I, Wada K, Furuse J, Matsuyama Y, Unno M; Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP). Motoi F, et al. Among authors: sho m. Jpn J Clin Oncol. 2019 Feb 1;49(2):190-194. doi: 10.1093/jjco/hyy190. Jpn J Clin Oncol. 2019. PMID: 30608598 Clinical Trial.
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.
Purcell JW, Tanlimco SG, Hickson J, Fox M, Sho M, Durkin L, Uziel T, Powers R, Foster K, McGonigal T, Kumar S, Samayoa J, Zhang D, Palma JP, Mishra S, Hollenbaugh D, Gish K, Morgan-Lappe SE, Hsi ED, Chao DT. Purcell JW, et al. Among authors: sho m. Cancer Res. 2018 Jul 15;78(14):4059-4072. doi: 10.1158/0008-5472.CAN-18-0327. Epub 2018 May 15. Cancer Res. 2018. PMID: 29764866
Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).
Ioka T, Kanai M, Kobayashi S, Sakai D, Eguchi H, Baba H, Seo S, Taketomi A, Takayama T, Yamaue H, Takahashi M, Sho M, Kamei K, Fujimoto J, Toyoda M, Shimizu J, Goto T, Shindo Y, Yoshimura K, Hatano E, Nagano H; Kansai Hepatobiliary Oncology Group (KHBO). Ioka T, et al. Among authors: sho m. J Hepatobiliary Pancreat Sci. 2023 Jan;30(1):102-110. doi: 10.1002/jhbp.1219. Epub 2022 Aug 9. J Hepatobiliary Pancreat Sci. 2023. PMID: 35900311 Free PMC article. Clinical Trial.
Clinical practice guidelines for duodenal cancer 2021.
Nakagawa K, Sho M, Fujishiro M, Kakushima N, Horimatsu T, Okada KI, Iguchi M, Uraoka T, Kato M, Yamamoto Y, Aoyama T, Akahori T, Eguchi H, Kanaji S, Kanetaka K, Kuroda S, Nagakawa Y, Nunobe S, Higuchi R, Fujii T, Yamashita H, Yamada S, Narita Y, Honma Y, Muro K, Ushiku T, Ejima Y, Yamaue H, Kodera Y. Nakagawa K, et al. Among authors: sho m. J Gastroenterol. 2022 Dec;57(12):927-941. doi: 10.1007/s00535-022-01919-y. Epub 2022 Oct 19. J Gastroenterol. 2022. PMID: 36260172 Free PMC article.
Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis.
Okusaka T, Nakamura M, Yoshida M, Kitano M, Ito Y, Mizuno N, Hanada K, Ozaka M, Morizane C, Takeyama Y; Committee for Revision of Clinical Guidelines for Pancreatic Cancer of the Japan Pancreas Society. Okusaka T, et al. Int J Clin Oncol. 2023 Apr;28(4):493-511. doi: 10.1007/s10147-023-02317-x. Epub 2023 Mar 15. Int J Clin Oncol. 2023. PMID: 36920680 Free PMC article.
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Ueno H, et al. Among authors: sho m. J Clin Oncol. 2013 May 1;31(13):1640-8. doi: 10.1200/JCO.2012.43.3680. Epub 2013 Apr 1. J Clin Oncol. 2013. PMID: 23547081 Clinical Trial.
Neoadjuvant Chemotherapy with Gemcitabine and S-1 versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP05 Trial.
Unno M, Motoi F, Matsuyama Y, Satoi S, Toyama H, Matsumoto I, Aosasa S, Shirakawa H, Wada K, Fujii T, Yoshitomi H, Takahashi S, Sho M, Ueno H, Kosuge T. Unno M, et al. Among authors: sho m. Ann Surg. 2025 Apr 16. doi: 10.1097/SLA.0000000000006730. Online ahead of print. Ann Surg. 2025. PMID: 40235447
Prognostic significance of creatine kinase in resected pancreatic cancer.
Kohara Y, Yasuda S, Nagai M, Nakamura K, Matsuo Y, Terai T, Doi S, Sakata T, Sho M. Kohara Y, et al. Among authors: sho m. J Hepatobiliary Pancreat Sci. 2024 Dec;31(12):906-916. doi: 10.1002/jhbp.12081. Epub 2024 Nov 3. J Hepatobiliary Pancreat Sci. 2024. PMID: 39489619
Clinical significance and therapeutic implication of CD200 in pancreatic cancer.
Kinoshita S, Terai T, Nagai M, Nakamura K, Kohara Y, Yasuda S, Matsuo Y, Doi S, Sakata T, Migita K, Ouji-Sageshima N, Ito T, Sho M. Kinoshita S, et al. Among authors: sho m. Pancreatology. 2024 Dec;24(8):1280-1287. doi: 10.1016/j.pan.2024.10.007. Epub 2024 Oct 12. Pancreatology. 2024. PMID: 39419752
356 results